Arkadiusz Dudek
Health Partners Institute · Masonic Cancer Center, University of Minnesota
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Arkadiusz Dudek as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:17 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT04589832 · Study of PAC-1 and Entrectinib for Patients With Metastatic Uveal MelanomaArkadiusz Z. Dudek, MD · terminated · Uveal Melanoma · principal investigator
- Ph2NCT01085630 · Pemetrexed Disodium/Observation in Treating Patients W/ Malignant Pleural Mesothelioma w/Out Progressive Disease After 1st Line ChemotherapyAlliance for Clinical Trials in Oncology · completed · Malignant Mesothelioma · study chair
- Ph2NCT01056601 · Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine TherapyMasonic Cancer Center, University of Minnesota · terminated · Pancreatic Cancer · principal investigator
- Ph2NCT00748163 · Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Sunitinib as First-Line Therapy in Treating Patients With Stage IV Non-Small Cell Lung CancerMasonic Cancer Center, University of Minnesota · withdrawn · Lung Cancer · principal investigator
- Ph2NCT00726739 · Aldesleukin With or Without Vaccine Therapy in Treating Patients With Stage IV MelanomaMasonic Cancer Center, University of Minnesota · completed · Stage IV Melanoma · principal investigator
- Ph1NCT00622674 · Bortezomib and Cetuximab in Treating Patients With Advanced Solid TumorsMasonic Cancer Center, University of Minnesota · completed · Breast Cancer, Colorectal Cancer, Head and Neck Cancer · principal investigator
- Ph1NCT00620295 · Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid TumorsMasonic Cancer Center, University of Minnesota · completed · Breast Cancer, Colorectal Cancer, Head and Neck Cancer · principal investigator
- Ph2NCT00509041 · Dasatinib in Treating Patients With Previously Treated Malignant MesotheliomaAlliance for Clinical Trials in Oncology · completed · Malignant Mesothelioma · study chair
- Ph2NCT00365547 · Topotecan and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Did Not Respond to Previous Systemic ChemotherapyMasonic Cancer Center, University of Minnesota · completed · Lung Cancer · principal investigator
- Ph2NCT00281827 · Carboplatin, Gemcitabine, and Thalidomide in Patients Undergoing Surgery for Stage II or III Non-Small Cell Lung CancerMasonic Cancer Center, University of Minnesota · terminated · Lung Cancer · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:17 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- AUTOLOGOUS LMI VACCINE FOR MELANOMA AND RENAL CELL CARCINOMAM01RR000400 · NCRR · UNIVERSITY OF MINNESOTA · fiscal years 2004 to 2006 · $2,510 awarded in 2006Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Alliance for Clinical Trials in Oncology Member Site CoreU10CA180821 · NCI · ALLIANCE NCTN FOUNDATION · PI Evanthia Galanis · fiscal years 2014 to 2026Named on NCT01085630
- Cancer and Leukemia Group BU10CA031946 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI Monica M Bertagnolli · fiscal years 1985 to 2013Named on NCT01085630, NCT00509041
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:17 UTC. The ranking covers the 200 most relevant of 55 PubMed records, and a shared surname and initials can bring in a namesake. All 55 on PubMed
- Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial.Lancet Oncol · 2012357 citationsRCR 9.0
- Intravenous amiodarone for the prevention of atrial fibrillation after open heart surgery: the Amiodarone Reduction in Coronary Heart (ARCH) trial.J Am Coll Cardiol · 1999207 citationsRCR 6.6
- 168 citationsRCR 6.7
- First in human phase I trial of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced cancer.Clin Cancer Res · 2007151 citationsRCR 2.8
- A phase 2 trial of dasatinib in advanced melanoma.Cancer · 2011126 citationsRCR 2.9
- Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer.J Clin Oncol · 2002121 citationsRCR 3.0
- 115 citationsRCR 5.4
- Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer.J Clin Oncol · 201097 citationsRCR 2.4
- Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study.Ann Rheum Dis · 201794 citationsRCR 3.9
- Cisplatin, irinotecan, and bevacizumab for untreated extensive-stage small-cell lung cancer: CALGB 30306, a phase II study.J Clin Oncol · 201179 citationsRCR 1.7